Clinical radioimmunotherapy

Seminars in Radiation Oncology

Volumn 10, Issue 2, 2000, Pages 73-93

  Knox, Susan J ^a,b,c   Meredith, Ruby F ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA HOSPITAL   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; ASTATINE 211; BISMUTH; COPPER 67; IODINE 125; IODINE 131; LUTETIUM; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM 186; RITUXIMAB; SAMARIUM 153; YTTRIUM 90;

BLOOD TOXICITY; BRAIN EDEMA; BRAIN TUMOR; GASTROINTESTINAL TOXICITY; GENETIC ENGINEERING; HUMAN; LEUKEMIA; LYMPHOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; REVIEW; SOLID TUMOR;

EID: 0034075573     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(00)80045-4     Document Type: Article

References (198)

1. (suppl) Larson SM Improving the balance between treatment and diagnosis: A role for radioimmunodetection Cancer Res 55 1995 5756s 5758s
2. Harrison KA Tempero MA Diagnostic use of radiolabeled antibodies for cancer Oncology 9 1995 625 631
3. DeNardo GL deNardo SJ Overview of obstacles and opportunities for radioimmunotherapy of cancer Goldberg D Cancer Therapy With Radiolabeled Antibodies 1995 CRC Press Boca Raton, FL 141 154
4. Wilder RB DeNardo GL DeNardo SJ Radioimmunotherapy: Recent results and future directions J Clin Oncol 14 1996 1383 1400
5. Meredith RF Buchsbaum DJ Radioimmunotherapy of solid tumors Henkin RE Boles MA Dillehay GL Nuclear Medicine: Principles and Practice 1996 Mosby St. Louis, MO 601 608
6. Buschsbaum DJ Langmuir VK Wessels BW Experimental radioimmunotherapy Med Phys 20 1993 551 567
7. Zola H Monoclonal antibodies, the Second Generation 1995 BIOS Oxford
8. Tempest PR Bremner P Lambert M Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo Biotechnology 9 1991 266 271
9. Order SE Stillwagon GB Klein JL Iodine 131-antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study J Clin Oncol 3 1985 1573 1582
10. 131I-antiferritin: An RTOG study Int J Radiat Oncol Biol Phys 20 1991 953 963
11. McCready DR Balch CM Fidler IJ Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo J Natl Cancer Inst 81 1989 682 687
12. Khazaeli MB Conry RM LoBuglio AF Human immune response to monoclonal antibodies J Immunother 15 1994 42 52
13. 131I-chimeric B72.3 antibody therapy Antib Immunoconj Radiopharm 6 1993 39 46
14. Weiden PL Wolf SB Breitz HB Human anti-mouse antibody suppression with cyclosporin A Cancer 73 1994 1093 1097
15. Dhingra K Fritsche H Murray JL Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: Phase I study Adv Exp Med Biol 353 1994 193 202
16. Zimmer AM Rosen ST Spies SM Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: Analysis of retreatment following plasmapheresis J Nucl Med 29 1988 174 180
17. DeNardo GL Maddock SW Sgouros G Immunoadsorption: An enhancement strategy for radioimmunotherapy J Nucl Med 34 1993 1020 1027
18. Reichmann L Clark M Waldmann H Reshaping human antibodies for therapy Nature 332 1988 323 327
19. Mark GE Reengineered monoclonal antibodies Antib Immunoconjug Radiopharm 5 1992 347
20. Irie RF Morton DL Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2 Proc Natl Acad Sci U S A 83 1986 8694 8698
21. Khazaeli MB Wheeler R Rogers K Initial evaluation of a human immunoglobulin M monoclonal antibody (HAIA) in humans J Biol Response Mod 9 1990 178 184
22. Wessels BW Rogus RE Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies Med Phys 11 1984 638 645
23. Yorke ED Beaumier PL Wessles BW Optimal antiody-radionuclide combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics Int J Radiat Appl Instrum [B] 18 1991 827 835
24. Mausner LF Srivastava SC Selection of radionuclides for radioimmunotherapy Med Phys 20 1993 503 509
25. Meredith RF, Buchsbaum DJ, Knox SJ: Radionuclide dosimetry and radioimmunotherapy of cancer, in Abrams P, Fritzberg AR (eds): Radioimmunotherapy of Cancer. New York, NY, Marcel Dekker (in press)
26. Maloney DG Levy R Campbell MJ Monoclonal antibody therapy Mendelsohn J Howley PM Israel MA The Molecular Basis of Cancer 1995 Saunders Philadelphia, PA 460 510
27. Meredith RF, Buchsbaum D, Knox SJ: Radioimmunotherapy, in Tepper JE, Gunderson LL (eds): Clinical Radiation Oncology. Philadelphia, PA, Saunders, (in press)
28. (suppl) Kaminski MS Zalenetz AD Press O Multicenter, Phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed lowgrade non-Hodgkin's lymphoma (NHL) (abstr) Blood 92 1998 316a
29. 2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration Cancer Res 50 1990 4105 4110
30. 125I monoclonal antibody in the management of primary glioblastoma multiforme Radiat Oncol Invest 3 1995 126 132
31. Breitz HB Fisher DR Weiden PL Dosimetry of rhenium 186-labeled monoclonal antibodies: Methods, prediction from technetium 99m-labeled antibodies, and results of phase I trials J Nucl Med 34 1993 908 917
32. Larson SM Carrasquillo JA Colcher DC Estimates of radiation-absorbed dose for intraperitoneally administered iodine 131-radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses J Nucl Med 32 1991 1661 1667
33. 177Lu-CC49 Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium Gatlinburg, TN 1999 158 171
34. Hnatowich DJ Chinol M Siebecker DA Patient biodistribution of intraperitoneally administered yttrium 90-labeled antibody J Nucl Med 29 1988 1428 1434
35. Colcher D Esteban J Carrasquillo JA Complementation of intracavitary and intravenous administration of monoclonal antibody (B72.3) in patients with carcinoma Cancer Res 47 1987 4218 4224
36. Stewart JSW Hird V Snook D Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies Int J Radiat Oncol Biol Phys 16 1989 405 413
37. Kalafonos HP Pawlikowska TR Hemingway A Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase J Nucl Med 30 1989 1636 1645
38. 131I-labeled anti-tenascin monoclonal antibody BC-2 Int J Cancer 51 1992 7 13
39. 90yttrium-labeled monoclonal antibody MUC 2-63 Epenetos A Monoclonal Antibodies 2: Applications in Clinical Oncology 1993 Chapman & Hall London 17 25
40. Pizer BL Papanastassiou V Moseley R Meningeal leukemia and medulloblastoma: Preliminary experience with intrathecal radioimmunotherapy Antib Immunoconj Radiopharm 4 1991 753 761
41. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results Clin Cancer Res 2 1996 963 972
42. Epenetos AA Munro AJ Stewart S Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies J Clin Oncol 5 1987 1890 1899
43. Heal A Tyson I Greenberg H Pharmacokinetics, dosimetry and clinical evaluation of 131-I-HMFG1 MoAb in the therapy of colorectal and ovarian carcinoma Antib Immunoconj Radiopharm 5 1992 1 12
44. Buckman R De Angelis C Shaw P Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3 Gynecol Oncol 47 1992 102 109
45. 90Y-labeled monoclonal antibodies as a third line of treatment in ovarian cancer: A phase 1–2 trial: Problems encountered and possible solutions Br J Cancer 10 1990 48 51
46. Jacobs AJ Fer M Su FM A phase I trial of rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response Obstet Gynecol 82 1993 586 593
47. 186Re-labeled monoclonal antibody: Methods and results Cancer Res 55 1995 5817s 5822s
48. Brietz HB Durham JS Fisher DR Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody J Nucl Med 36 1995 754 761
49. Crippa F Radioimmunotherapy of ovarian cancer Int J Biol Markers 8 1993 187 191
50. Meredith RF Partridge EE Khazaeli MB Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49 J Nucl Med 37 1996 1491 1496
51. 177Lu-CC49: A phase I/II study Gynecol Oncol 65 1997 94 101
52. 1 Tumor Targeting 2 1996 162
53. 90Y-Cyt-356 monoclonal antibody Clin Cancer Res 2 1996 1289 1297
54. Meredith RF Khazaeli MB Carabasi MH Radioimmunotherapy of prostate cancer Riva P Therapy of Malignancies With Radioconjugate Monoclonal Antibodies: Present Possibilities and Future Perspectives 1997 Harwood Academic Chur, Switzerland 321 331
55. *) in patients with metastatic hormone resistant prostate cancer (HRPC) Proc Am Soc Clin Oncol 18 1999 313a
56. 90Y]yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy Cancer Biother Radiopharm 14 1999 99 112
57. Carrasquillo JA Krohn KA Beaumier P Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments Cancer Treat Rep 68 1984 317 328
58. 90Yttrium antiferritin: Dose escalation and tumor dose Antib Immuniconj Radiopharm 1 1988 163 168
59. Vessella RI Radioimmunoconjugates in renal cell carcinoma Debruyne FMJ Bukowski RM Pontes JE Immunotherapy of Renal Cell Carcinoma 1991 Springer Verlag Heidelberg 38 46
60. Markoe AM Brady LW Wood D Treatment of gastrointestinal cancers using monoclonal antibodies Vaeth J Meyer JL Frontiers of Radiation Therapy Oncology 1990 Karger Press Basel 214 224
61. Goldenberg DM Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies Am J Gastroenterol 86 1991 1392 1403
62. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma Clin Cancer Res 1 1995 1447 1454
63. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma Cancer 85 1999 1828 1842
64. suppl Murray JL Macey DJ Grant EJ Enhanced TAG-72 expression, and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment Cancer Res 55 1995 5925s 5928s
65. 90Y MX-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A phase I trial Cancer Res 55 1995 5921s 5924s
66. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial Cancer Res 55 1995 5929s 5934s
67. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions Cancer Res 55 1995 5916s 5920s
68. Denardo SJ Richman CM Goldstein DS Yttrium-90/indium-111-DOTA-peptide-chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer Anticancer Res 17 1997 1735 1744
69. Breitz HB Weiden PL Vanderheyden JL Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials J Nucl Med 33 1992 1099 1112
70. abstr 70 Carabasi MH Meredith RF Marshall ME Multimodality therapy with autologous stem cell rescue for hormone resistant prostate cancer Presented at the AACR Basic and Clinical Aspects of Prostate Cancer Conference Rancho Mirage, CA December 1994 C26
71. Goldenberg D Cancer Therapy With Radiolabeled Antibodies 1995 CRC Press Boca Raton, FL
72. Meredith RF LoBuglio AF Recent progress in radioimmunotherapy for cancer Oncology 11 1997 979 984
73. Murray JL Radioimmunotherapy of colorectal cancer Goldenberg D Cancer Therapy With Radiolabeled Antibodies 1995 CRC Press Boca Raton, FL 173 187
74. Corcoran MC Press OW Matthews DC The role of radioimmunotherapy in bone marrow transplantation Curr Opin Hematol 3 1996 438 445
75. Tempero M Leichner P Dalrymple G High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial J Clin Oncol 15 1997 1518 1528
76. Crippa F Bolis G Seregni E Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 Mov 18: Clinical results in patients with minimal residual disease of ovarian cancer Eur J Cancer 31A 1995 686
77. Hird V Maraveyas A Snook D Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody Br J Cancer 68 1993 403 406
78. Fein DA Morgan LS Marcus RB Jr Stage III ovarian carcinoma: An analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage Int J Radiat Oncol Biol Phys 29 1994 169 176
79. 131I radiolabeled monoclonal antibodies Goldenberg DM Cancer Therapy With Radiolabeled Antibodies 1995 CRC Press Boca Raton, FL 203 227
80. Brady LW Markoe A Woo DV Iodine 125-labeled anti-epidermal growth factor receptor 425 in the treatment of malignant astrocytomas: A pilot study J Neurosurg Sci 34 1990 243 249
81. 125I-labeled monoclonal antibody against epidermal growth factor receptor Antib Immunoconj Radiopharm 3 1990 169
82. Kemshead JT Papanastassiou V Coakham HB Monoclonal antibodies in the treatment of central nervous system malignancies Eur J Cancer 28 1992 511 513
83. Goldenberg DM Horowitz JA Sharkey RM Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with Iodine-131-labeled LL2 monoclonal antibody J Clin Oncol 9 1991 548 564
84. 131I]anti-B1 (anti-CD20) antibody N Engl J Med 329 1993 459 465
85. Press OW Eary JF Applebaum FR Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support N Engl J Med 329 1993 1219 1224
86. Kuzel T Rosen ST Zimmer AM A phase I escalating-dose safety, dosimetry, and efficacy study of radiolabeled monoclonal antibody Lym-1 Cancer Biother 8 1993 3 16
87. 131I-Lym-1 in patients with non-Hodgkin's lymphoma Antib Immunoconj Radiopharm 6 1993 1 11
88. 131I]anti-B1 (anti-CD20) radioimmunotherapy (RIT) for refractory B-cell lymphomas (abstr) Blood 82 1993 332A
89. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement Goldenberg DM Cancer Therapy With Radiolabeled Antibodies 1994 CRC Press Boca Raton, FL 217 227
90. Lewis JP DeNardo GL DeNardo SJ Radioimmunotherapy of lymphoma: A UC Davis experience Hybridoma 14 1995 115 120
91. 131I-Lym-1 Cancer Res 50 1990 1014s 1016s
92. Kaminski MS Fig LM Zasadmy KR Imaging, dosimetry, and radioimmunotherapy with iodine-131-labeled anti-CD37 antibody in B-cell lymphoma J Clin Oncol 10 1992 1696 1711
93. Czuczman MS Straus DJ Digvi CR Phase-I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma J Clin Oncol 11 1993 2021 2029
94. 90Y-conjugated anti-idiotype monoclonal antibody Cancer Res 50 1990 1022s
95. White CA Halpern SE Parker BA Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 antiidiotype monoclonal antibodies Blood 87 1996 3640 3649
96. Press OW Eary JF Badger CC Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti CD37) antibody J Clin Oncol 7 1989 1027 1038
97. Badger CC Eary JF Brown S Therapy of lymphoma with I-131-labeled anti-idiotype antibodies (anti-id) Proc AACR 28 1987 388
98. Kaminski MS Zasadny KR Francis IR Iodine 131-anti-B1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 14 1996 1974 1981
99. Liu SY Eary JF Petersdorf SH Follow-up of relapsed B-cell lymphoma patients treated with iodine 131-labeled anti-CD20 antibody and autologous stem cell rescue J Clin Oncol 16 1998 3270 3278
100. suppl Vose J Colcher D Bierman P I-131-LL2 (anti-CD20) radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphoma (NHL): Results of a repetitive dosing trial J Nucl Med 38 1997 59
101. Kaminski MS Estis M Regan J Frontline treatment of advanced B-cell low-grade lymphoma with radiolabeled anti-B1 antibody: Initial experience J Clin Oncol 16 1997 15a
102. Davis T Knox SJ Radioimmunoconjugate therapy of non-Hodgkin's lymphoma Grossbard ML Monoclonal Antibody-Based Therapy of Cancer 1998 Marcel Dekker New York, NY 113 136
103. 90Y-labeled anti-CD20 monoclonal antibody-based therapy of recurrent B-cell lymphoma Clin Cancer Res 2 1996 457 470
104. Press OW Eary JF Applebaum FR Radiolabeled antibody therapy of lymphomas DeVita VT Hellman S Rosenberg SA Biologic Therapy of Cancer 1994 Lippincott Philadelphia, PA 1 13
105. 131I-B1 (anti CD20) antibody therapy with autologous stem-cell transplantation for relapsed B-cell lymphomas Lancet 346 1995 336 340
106. 90Y-labeled humanized LL2 Anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma Clin Cancer Res 5 1999 3292 3303
107. Vose JM, Colcer D, Gobar L, et al: Phase I/II trial of multiple dose 131-iodine Mab LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma, in Leukemia and Lymphoma (in press)
108. 67CU-2IT-BAT-LYM-1 for non-Hodgkin's lymphoma J Nucl Med 1999
109. (abstr) Stagg R Wahl RL Estes J Phase I/II study of iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL) Proc Am Soc Clin Oncol 17 1998 39a
110. Vose JM, Wahl RL, Saleh M, et al: Multicenter Phase II study of iodine I-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol (in press)
111. (abstr) Kaminski MS Gribbin T Estes J Iodine-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): Clinical and molecular remissions Proc Am Soc Clin Oncol 17 1998 2a
112. suppl Weiden P Breitz H Press OW Radioimmunotherapy (RIT) in the treatment of non-Hodgkin's lymphoma (NHL): Advantage of pretargeted RIT (PRIT) (abstr) Blood 92 1998 414a
113. Witzig T Wiseman G White CA Phase I/II trial of Zevalin (90 yttrium ibritumomab tiuxetan; IDEC-Y2B8) radioimmunotherapy for treatment of relapsed or refractory CD20 positive B-cell non-Hodgkin's lymphoma J Clin Oncol 17 1999 3793 3803
114. Zimmer AM Kaplan EH Kazikiewicz JM Pharmacokinetics of I-131 T101 monoclonal antibody in patients with chronic lymphocytic leukemia Antib Immunoconj Radiopharm 1 1988 291 303
115. Rosen ST Zimmer AM Goldman LR Progress in the treatment of cutaneous T cell lymphomas with radiolabeled monoclonal antibodies Int J Radiat Appl Instrum [B] 16 1989 667 668
116. Raubitschek AA Yttrium 90-labeled T101 in the treatment of hematologic malignancies Proceedings of the Fifth International Conference on Monoclonal Antibody Conjugates for Cancer San Diego, CA 1990
117. Waldmann TA White JD Carrasquillo JA Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac Blood 86 1995 4063 4075
118. Lenhard RE Order SE Spunberg JJ Isotopic immunoglobin: A new system therapy for advanced Hodgkin's disease J Clin Oncol 3 1985 1269 1300
119. Bierman PJ Vose JM Leichner PK Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease J Clin Oncol 11 1993 698 703
120. [published erratum J Clin Oncol 9:1516, 1991] Vriesendorp HM Herpst JM Germack MA Phase I–II studies of yttrium-labeled antiferritin treatment for endstage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 J Clin Oncol 9 1991 918 928
121. Herpst JM Klein JL Leichner PK Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment J Clin Oncol 13 1995 2394 2400
122. suppl Morton JD Quadri SM Tang XZ Yttrium 90-labeled antiferritin therapy in patients with refractory end-stage Hodgkin's disease (abstr) Int J Radiat Oncol Biol Phys 30 1994 181
123. suppl Vriesendorp HM Morton JD Quadri SM Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease Cancer Res 55 1995 5888s 5892s
124. suppl Jurcic JG Caron PC Nikula TK Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 55 1995 5908s 5910s
125. Jurcic JG Caron PC Miller WH Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195 Lancet 9 1995 244 248
126. Caron PC Schwartz MA Co MS Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia Cancer 73 1994 1049 1056
127. Caron PC Jurcic JG Scott AM A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity Blood 83 1994 1760 1768
128. Scheinberg DA Antibody-mediated therapy of minimal residual leukemia: Use of humanized monoclonal antibodies and targeted alpha particles Proceedings of the European Biological Society 4th International Symposium on the Biological Therapy of Cancer Munich, Germany 1997
129. 131I anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 94 1999 1237 1247
130. 131I anti-CD45 antibody plus busulfan/cyclophosphamide in matched transplants for AML in first remission Blood 88 1996 142a
131. 131I-anti-B1 versus unlabeled-anti-B1 monoclonal antibody in patients with chemotherapy refractory low-grade non-Hodgkin's lymphoma Int J Radiat Oncol Biol Phys 39 1997 326
132. Schlom J Molinolo A Simpson JF Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy J Natl Cancer Inst 82 1990 763 771
133. Meredith RF Khazaeli MB Liu T Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer J Nucl Med 33 1992 1648 1653
134. Blumenthal RD Sharkey RM Kashi R Suppression of tumor vascular activity by radioantibody therapy: Implications for multiple cycle treatments Sel Cancer Ther 7 1991 9 16
135. Blumenthal RD Sharkey RM Goldenberg DM Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression J Natl Cancer Inst 84 1992 399 407
136. Neta R Douches S Oppenheim JJ Interleukin 1 is a radioprotector J Immunol 136 1986 2483 2485
137. 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy J Natl Cancer Inst 81 1989 194 199
138. Begent RHJ Bagshawe KD Pedley RB Use of second antibody in radioimmunotherapy Natl Cancer Inst Monogr 3 1987 59 61
139. Carabasi MH Meredith RF Marshall ME Multimodality therapy with autologous stem cell rescue for hormone-resistant prostate cancer AACR Basic and Clinical Aspects of Prostate Cancer Conference, Rancho Mirage, CA 1994
140. Dillman RO Monoclonal antibodies for treating cancer Ann Intern Med 111 1989 592 603
141. 90Yttrium J Clin Oncol 17 1998 438a
142. (abstr) Weiden P Small EJ Hudes GR A Phase II trial of pretargeted radioimmunotherapy (PRIT) in patients with metastatic hormone resistant prostate cancer (HRPC) J Clin Oncol 18 1999 313a
143. Knox SJ, Goris ML, Tempero M, et al: Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/ streptavidin in patients with metastatic colon cancer. Clin Cancer Res (in press)
144. Meredith RF Johnson TK Plott G Dosimetry of solid tumors Med Phys 20 1993 583 592
145. Griffith MH Yorke ED Wessels BW Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy J Nucl Med 29 1988 1795 1809
146. Larson SM Pentlow KS Volkow ND PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma J Nucl Med 33 1992 2020 2023
147. (abstr) Jurcic JG McDevitt MR Sgouvos G Phase I trial of targeted alpha-particle therapy for myeloid leukemias with Bismuth-213-Hum 195 (an-CD33) Proc ASCO 18 1999 7a
148. Siegel JA Goldenberg DM Badger CC Radioimmuno-therapy dose estimation in patients with B-cell lymphoma Med Phys 20 1993 579 582
149. 186Re)-labeled antibody in patients with cancer: Report of a pilot phase I study Antib Immunoconj Radiopharm 3 1990 99
150. Eary JF Press OW Badger CC Imaging and treatment of B-cell lymphoma J Nucl Med 31 1990 1257 1268
151. 131I-CC49 in colorectal cancer Cancer 73 1994 1057 1066
152. 90Yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL) abstr 260 J Nucl Med 40 1999 64
153. suppl Knox S Overview of studies on experimental radioimmunotherapy Cancer REs 55 1995 5832s 5836s
154. Buchsbaum DJ Experimental radioimmunotherapy and methods to increase therapeutic efficacy Goldberg DM Cancer Therapy With Radiolabeled Antibodies 1994 CRC Press Boca Raton, FL 115 140
155. van Osdol W Fujimori K Weinstein JN An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a “binding site barrier” Cancer Res 51 1991 4776 4784
156. Chatal JF Saccavini JC Fumoleau P Immunoscintigraphy of colon cancer J Nucl Med 25 1984 307 314
157. 2 fragments of monoclonal antiferritin in nude mouse model J Nucl Med 34 1993 2152 2159
158. Msirikale JS Klein JL Schroeder J Radiation enhancement of radiolabeled antibody deposition in tumors Int J Radiat Oncol Biol Phys 13 1987 1839 1844
159. 131I anti-CEA—a Radiation Therapy Oncology Group Study Int J Radiat Oncol Biol Phys 13 1987 687 695
160. Gridley DS Mackensen DG Slater JB Effects of proton irradiation on radiolabeled monoclonal antibody uptake in human colon tumor xenografts J Immunother Emphasis Tumor Immunol 17 1995 229 237
161. 2 uptake in tumor using hyperthermial J Nucl Med 33 1992 958 959
162. DeNardo GL DeNardo SJ Lamborn KR Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG-IL-2 Antib Immunoconj Radiopharm 4 1991 859 870
163. DeNardo SJ Mirick GR Korger LA The biologic window for chimeric L6 radioimmunotherapy Cancer 73 1994 1023 1032
164. 131I-labeled antibody therapy Radiat Res 128 1991 320 324
165. Wilder RB McGann JK Sutherland WR The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts Int J Radiat Oncol Biol Phys 28 1993 119 126
166. Wilder RB Langmuir VK Mendonca HL Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts Cancer Res 53 1993 3022 3027
167. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo Radiat Res 132 1992 351 358
168. 177Lu-CC49 Min Biotechnol 10 1998 100 107
169. DeNardo SJ Lamborn KR Korger LA The importance of time-dose relationships in enhancement strategies for RIT of breast cancer Tumor Target 2 1996 148 149
170. Fu KK Lam KN Rayner PA The influence of time sequence of cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma Int J Radiat Oncol Biol Phys 11 1985 2119 2124
171. Buchsbaum DJ Khazaeli MB Davis MA Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine Cancer 73 1994 999 1005
172. 90Y-lymphoma therapy Cancer 73 1994 966 973
173. (abstr) Blumenthal RD Soyne DX Lew W Use of antioxidant vitamins to reduce radioimmunotherapy-induced gastrointestinal and hematopoietic toxicity Proc AACR 40 1999 641
174. Schlom J Eggensperger D Colcher D Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates Cancer Res 52 1992 1067 1072
175. Divgi CR Scott AM Dantis L Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma J Nucl Med 36 1995 586 592
176. Meredith RF Bueschen AJ Khazaeli MB Treatment of metastatic prostate cancer with radiolabeled antibody CC49 J Nucl Med 35 1994 1017 1022
177. 111In-labeled anti-melanoma antibody 96.5 in melanoma patients J Natl Cancer Inst 80 1988 160 165
178. 131I-CC49) when given in combination with gamma interferon Cancer Res 53 1993 600 608
179. Kuhn JA Beatty BG Wong JY Interferon enhancement of radioimmunotherapy for colon carcinoma Cancer Res 51 1991 2335 2339
180. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer Clin Cancer Res 2 1996 1811 1818
181. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer Clin Cancer Res 5 1999 3254 3258
182. Wong JY Mivechi NF Paxton RJ The effects of hyperthermia on tumor carcinoembryonic antigen expression Int J Radiat Oncol Biol Phys 17 1989 803 808
183. Stickney DR Slater JB Kirk GA Bifunctional antibody: ZCE/CHH indium-111 BLEDTA-IV clinical imaging in colorectal cancer Antib Immunoconj Radiopharm 2 1989 1
184. Paganelli G Magnani P Siccardi AG Clinical application of the avidin-biotin system for tumor targeting Goldberg DM Cancer Therapy With Radiolabeled Antibodies 1995 CRC Press Boca Raton, FL 239 254
185. Smitsyn VV Mamontova AG Checkneva YY Rapid blood clearance of biotinylated IgG after infusion of avidin J Nucl Med 30 1989 66 69
186. Paganelli G Magnani P Fazio F Monoclonal antibody pretargeting techniques: The avidin-biotin system clinical oncology Epenetos AA Monoclonal Antibodies 2: Applications to Clinical Oncology 1993 Chapman & Hall London 171
187. Breitz HB Weiden PL Fritzberg AR Radiolabeled monoclonal antibodies for localization and treatment of metastatic cancer Oldham RK Principles of Cancer Biotherapy ed 3 1997 Kluwer Amsterdam 348 368
188. Bosslet K Steinstrasser A Hermentin P Generation of bispecific monoclonal antibodies for two-phase radioimmunotherapy Epenetos AA Monoclonal Antibodies: Applications to Clinical Oncology 1991 Chapman & Hall London 167 178
189. Chatal JF Faivre-Chauvet A Bardies M Bifunctional antibodies for radioimmunotherapy Hybridoma 14 1995 125 128
190. Buchsbaum DJ Sinkule JA Stites MS Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma Cancer Res 48 1988 2475 2482
191. suppl Mattes MJ Major PP Goldenberg DM Patterns of antigen distribution in human carcinomas Cancer Res 50 1990 880s 884s
192. Simpson JF Primus FJ Schlom J Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas Int J Biol Markers 6 1991 83 90
193. 2 fragments J Nucl Med 27 1986 1739 1745
194. Blumenthal RD Kashi R Stephens R Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p Cancer Immunol Immunother 32 1991 303 310
195. Fleshman JW Connett JM Neufeld DM Tumor localization and radioimaging with mixtures of radioiodinated monoclonal antibodies directed to different colon cancer associated antigens Int J Radiat Appl Instrum [B] 19 1992 659 668
196. Raben D Buchsbaum DJ Khazaeli MB Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene Gene Ther 3 1996 567 580
197. Buchsbaum DJ Raben D Stackhouse MA Approaches to enhance cancer radiotherapy employing gene transfer methods Gene Ther 3 1996 1042 1068
198. Rosenfeld ME Rogers BE Khazaeli MB Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo Clin Cancer Res 3 1997 1187 1194